An alteration of ganglioside composition in cisplatin-resistant lung cancer cell line

• Published in: Anticancer research Vol. 18; no. 4C; p. 2957
• Main Authors: Kiura, K, Watarai, S, Ueoka, H, Tabata, M, Gemba, K, Aoe, K, Yamane, H, Yasuda, T, Harada, M
• Format: Journal Article
• Language: English
• Published: Greece 01.07.1998
• Subjects: Antineoplastic Agents - pharmacology; Carcinoma, Small Cell - drug therapy; Carcinoma, Small Cell - metabolism; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Cisplatin - pharmacology; Drug Resistance, Neoplasm; Flow Cytometry; G(M2) Ganglioside - metabolism; G(M3) Ganglioside - metabolism; Humans; Lung Neoplasms - drug therapy; Lung Neoplasms - metabolism; Tumor Cells, Cultured
• ISSN: 0250-7005; 1791-7530

Previously we established cell lines resistant to Adriamycin and cisplatin to elucidate the mechanisms involved in acquired drug-resistance. In this study, we investigated ganglioside composition in drug-resistant cell lines. The Adriamycin-resistant cell line, SBC-3/ADM100, exhibited a ganglioside composition ratio similar to that of the parent SBC-3 cells. Densitometric analysis by resorcinol showed a 1.61-fold increase of ganglioside GM2 in SBC-3/ADM100 cells, when compared to the parent SBC-3 cells. The cisplatin-resistant cell line, SBC-3/CDDP, showed a simplified ganglioside pattern, expressing only gangliosides GM3 and GM2. SBC-3/CDDP cells showed a marked increase in ganglioside GM3. These findings suggest that the alteration of ganglioside composition may be actively involved in the acquisition of drug-resistance.